Guru Angad Dev Veterinary and Animal Sciences University

DROWNING PREVENTION RESEARCH SUMMIT KICKS OFF MULTI-YEAR EFFORT TO CHAMPION ADVANCEMENT AND INNOVATION IN DROWNING PREVENTION RESEARCH AND SAFETY

Retrieved on: 
Thursday, September 15, 2022

SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- On September 13-14, 2022 the National Drowning Prevention Alliance (NDPA.org) hosted the industry's first research summit solely dedicated to water safety and drowning prevention for children and adolescents - a critical issue and the single leading cause of death among children ages 1-4 years old.

Key Points: 
  • "The body of data available for drowning prevention has been historically weak leaving us to use best practices instead of evidence-informed approaches," said Adam Katchmarchi, Ph.D., M.S., Executive Director, NDPA.
  • "Our goal is to change that and bring all stakeholders together to collaborate on a unified research agenda."
  • The Drowning Prevention Research Summit was made possible through the generous funding of the Chuck & Ernestina Kreutzkamp Foundation.
  • The mission of the National Drowning Prevention Alliance is "United, we can prevent the tragedy of drowning."

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology

Retrieved on: 
Wednesday, August 31, 2022

Median duration of exposure to Isturisa from core study baseline to end of the extension was 130 weeks (range 1245).

Key Points: 
  • Median duration of exposure to Isturisa from core study baseline to end of the extension was 130 weeks (range 1245).
  • Recordati Rare Diseases is committed to improving the lives of patients with this rare, debilitating and life-threatening condition.
  • Long-term outcomes of osilodrostat in Cushings disease: LINC 3 study extension The European Journal of Endocrinology 2022.
  • Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.

Digital Medicine Society Rallies Global Healthcare Leaders to Collaborate on Digital Measurement for Alzheimer's Disease

Retrieved on: 
Monday, March 14, 2022

Increasingly, digital tools such as wearable sensors are being used to provide complete and precise information about the impact of disease on patients' lives.

Key Points: 
  • Increasingly, digital tools such as wearable sensors are being used to provide complete and precise information about the impact of disease on patients' lives.
  • "We are excited to collaborate with DiME in accelerating this transformation, especially given their track-record in delivering impactful insights to help realize digital medicines."
  • "Digital measures offer enormous promise to bolster collective understanding of Alzheimer's disease and related dementias," says Jian Yang, Associate Vice President of Digital Health at Eli Lilly and Company.
  • About the Digital Medicine Society: The Digital Medicine Society (DiMe) is the professional society serving the digital medicine community, driving scientific progress and broad acceptance of digital medicine to enhance public health.